Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections

Evidence-Based Child Health

Volumn 8, Issue 4, 2013, Pages 1297-1371

  Schuetz, Philipp ^a   Muller, Beat ^b   Christ Crain, Mirjam ^c   Stolz, Daiana ^c   Tamm, Michael ^c   Bouadma, Lila ^d   Luyt, Charles E ^e   Wolff, Michel ^d   Chastre, Jean ^e   Tubach, Florence ^f   Kristoffersen, Kristina B ^g   Burkhardt, Olaf ^h   Welte, Tobias ^h   Schroeder, Stefan ⁱ   Nobre, Vandack ^j   Wei, Long ^k   Bhatnagar, Neera ^l   Bucher, Heiner C ^m   Briel, Matthias ^m  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f BICHAT HOSPITAL   (France)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ Department of Anesthesiology and Intensive Care Medicine   (Germany)

^j GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^k Fudan University   (China)

^l MCMASTER UNIVERSITY   (Canada)

^m UNIVERSITY HOSPITAL BASEL   (Switzerland)

more..

Author keywords

Acute Disease; Anti Bacterial Agents ; Bacterial Infections blood; ; Biological Markers blood ; blood ; Calcitonin ; Cause of Death; drug therapy; mortality ; Humans; Infections blood; ; MeSH check words; Protein Precursors ; Randomized Controlled Trials as Topic; Respiratory Tract; therapeutic use ; Treatment Failure

Indexed keywords

ANTIBIOTIC AGENT; PROCALCITONIN;

ARTICLE; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG EXPOSURE; DRUG TREATMENT FAILURE; DRUG USE; FOLLOW UP; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; META ANALYSIS; MORTALITY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; RESPIRATORY TRACT INFECTION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS [*THERAPEUTIC USE]; BACTERIAL INFECTIONS [BLOOD; *DRUG THERAPY; MORTALITY]; BIOLOGICAL MARKERS [BLOOD]; CALCITONIN [*BLOOD]; CAUSE OF DEATH; HUMANS; INFECTIONS [BLOOD; *DRUG THERAPY; MORTALITY]; MESH CHECK WORDS; PROTEIN PRECURSORS [*BLOOD]; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY TRACT; TREATMENT FAILURE;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; CALCITONIN; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; PROTEIN PRECURSORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY TRACT INFECTIONS;

EID: 84880357102     PISSN: None     EISSN: 15576272     Source Type: Journal    
DOI: 10.1002/ebch.1927     Document Type: Article

References (149)

1. References to studies included in this review
2. Bouadma 2010 {published data only}
3. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, et al.Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010;375(9713):463-74.
4. Briel 2008 {published data only}
5. Briel M, Schuetz P, Mueller B, Young J, Schild U, Nusbaumer C, et al.Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Archives of Internal Medicine 2008;168(18):2000-7.
6. Burkhardt 2010 {published data only}
7. Burkhardt O, Ewig S, Haagen U, Giersdorf S, Hartmann O, Wegscheider K, et al.Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. European Respiratory Journal 2010;36(3):601-7.
8. Christ-Crain 2004 {published data only}
9. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay M, Huber P, Tamm M, et al.Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004;1363(9409):600-7.
10. Christ-Crain 2006 {published data only}
11. Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber PR, et al.Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. American Journal of Respiratory and Critical Care Medicine 2006;174(1):84-93.
12. Hochreiter 2009 {published data only}
13. Hochreiter M, Kohler T, Schweiger AM, Keck FS, Bein B, von Spiegel T, et al.Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Critical Care 2009;13(3):R83.
14. Kristoffersen 2009 {published data only}
15. Kristoffersen KB, Sogaard OS, Wejse C, Black FT, Greve T, Tarp B, et al.Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission--a randomized trial. Clinical Microbiology and Infection 2009;15(5):481-7.
16. Long 2009 {published data only}
17. Long W, Deng XQ, Tang JG, Xie J, Zhang YC, Zhang Y, et al.Procalcitonin-guidance for reduction of antibiotic use in low-risk outpatients with community acquired pneumonia. Zhonghua Nei Ke Za Zhi 2009;48(3):216-9.
18. Long 2011 {published data only}
19. Long W, Deng X, Zhang Y, Lu G, Xie J, Tang J. Procalcitonin-guidance for reduction of antibiotic use in low-risk outpatients with community acquired pneumonia. Respirology 2011;76(1):266-9.
20. Nobre 2008 {published data only}
21. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. American Journal of Respiratory and Critical Care Medicine 2009;177(5):498-505.
22. Schroeder 2009 {published data only}
23. Schroeder S, Hochreiter M, Koehler T, Schweiger AM, Bein B, Keck FS, et al.Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Archives of Surgery 2009;394(2):221-6.
24. Schuetz 2009 {published data only}
25. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, et al.Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009;302(10):1059-66.
26. Stolz 2007 {published data only}
27. Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C, et al.Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007;131(1):9-19.
28. Stolz 2009 {published data only}
29. Stolz D, Smyrnios N, Eggimann P, Pargger H, Thakkar N, Siegemund M, et al.Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. European Respiratory Journal 2009;34(6):1364-75.
30. References to studies excluded from this review
31. Esposito 2012 {published data only}
32. Esposito S,Tagliabue C, Picciolli I, Semino M, Sabatini C, Consolo S, et al. Procalcitonin measurements for guiding antibiotic treatment in pediatric pneumonia. Respiratory Medicine 2011;105(12):1939-45.
33. Heyland 2011 {published data only}
34. Heyland DK, Johnson AP, Reynolds SC, Muscedere J. Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Critical Care Medicine 2011;39(7):1792-9.
35. Jensen 2011 {published data only}
36. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, et al.Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Critical Care Medicine 2011;39(9):2048-58.
37. Jones 2007 {published data only}
38. Jones AE, Fiechtl JF, Brown MD, Ballew JJ, Kline JA. Procalcitonin test in the diagnosis of bacteremia: a meta-analysis. Annals of Emergency Medicine 2007;50(1):34-41.
39. Kook 2012 {published data only}
40. Kook JL, Chao SR, Le J, Robinson PA. Impact of the use of procalcitonin assay in hospitalised patients with pneumonia at a community care hospital. Infection Control and Hospital Epidemiology 2012;33(4):424-6.
41. Liew 2011 {published data only}
42. Liew YX, Chlebicki MP, Lee W, Hsu LY, Kwa AL. Use of procalcitonin (PCT) to guide discontinuation of antibiotic use in an unspecified sepsis is an antimicrobial stewardship program (ASP). European Journal of Clinical Microbiology and Infectious Diseases 2011;30:853-5.
43. Maravić-Stojković 2011 {published data only}
44. Maravić-Stojković V, Lausević-Vuk L, Jović M, Ranković A, Borzanović M, Marinković J. Procalcitonin-based therapeutic strategy to reduce antibiotic use in patients after cardiac surgery: a randomized controlled trial. Srpski Arhiv za Celokupno Lekarstvo 2011;139(11-2):736-42.
45. Qu 2012 {published data only}
46. Qu R, Ji Y, Ling Y, Ye CY, Yang SM, Liu YY, et al. Procalcitonin is a good tool to guide duration of antibiotic therapy in patients with severe acute pancreatitis. A randomized prospective single-center controlled trial. Saudi Medical Journal 2012;33(4):382-7.
47. Saeed 2011 {published data only}
48. Saeed K, Dryden M, Bourne S, Paget C, Proud A. Reduction in antibiotic use through procalcitonin testing in patients in the medical admission unit or intensive care unit with suspicion of infection. Journal of Hospital Infection 2011;78:289-92.
49. Schuetz 2010 {published data only}
50. Schuetz P, Batschwaroff M, Dusemund F, Albrich W, Burgi U, Maurer M, et al.Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a post-study survey. European Journal of Clinical Microbiology and Infectious Diseases 2010;29(3):269-77.
51. Simmonds 2005 {published data only}
52. Simmonds MC, Higgins JP, Stewart LA, Tierney JF, Clarke MJ, Thompson SG. Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clinical Trials 2005;2(3):209-17.
53. Simon 2004 {published data only}
54. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clinical Infectious Diseases 2004;39(2):206-17.
55. Stocker 2010 {published data only}
56. Stocker M, Fontana M, el Helou S, Wegscheider K, Berger TM. Use of procalcitonin-guided decision-making to shorten antibiotic therapy in suspected neonatal early-onset sepsis: prospective randomized intervention trial. Neonatology 2010;97(2):165-74.
57. Tang 2007 {published data only}
58. Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infectious Diseases 2007;7(3):210-7.
59. Tang 2009 {published data only}
60. Tang H, Huang T, Jing J, Shen H, Cui W. Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. Infection 2009;37(6):497-507.
61. Uzzan 2006 {published data only}
62. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Critical Care Medicine 2006;34(7):1996-2003.
63. References to studies awaiting assessment
64. Beni 2011{unpublished data only}
65. Benni I. Procalcitonin-aided antibiotic therapy management in hospital-acquired pneumonia and healthcare-associated pneumonia: A randomised controlled trial (the prohap study). Poster at the Respirology. Conference: 16th Congress of the Asian Pacific Society of Respirology Shanghai, China. Shanghai, China, 2011; Vol. 16:68.
66. References to ongoing studies
67. NCT00407147 {published data only}
68. Procalcitonin level to discontinue antibiotics on ICU patients with no obvious site of infection. Ongoing study 29 November 2006.
69. NCT00692848 {unpublished data only}
70. Impact of procalcitonin on the management of children aged 1 to 36 month presenting with a fever without a source. Ongoing study November 2006.
71. NCT00832039 {published data only}
72. Placebo controlled trial of sodium selenite and procalcitonin guided antimicrobial therapy in severe sepsis (SISPCT). Ongoing study 28 January 2009.
73. NCT00854932 {published data only}
74. Neonatal Procalcitonin Intervention Study (NeoPInS). Ongoing study 2 March 2009.
75. NCT00914550 {published data only}
76. Use of procalcitonin level for guidance of the treatment of suspected community acquired pneumonia. Ongoing study June 2009.
77. NCT00987818 {published data only}
78. Procalcitonin guided versus conventional antibiotic therapy in patients with sepsis in the ICU. Ongoing study Unclear.
79. NCT01018199 {published data only}
80. Procalcitonin versus C-reactive protein to guide therapy in community acquired pneumonia (CAP-Marker). Ongoing study December 2009.
81. NCT01025180 {published data only}
82. Study of procalcitonin (procalcitonin)-guided antibiotic use in severe sepsis patients without obvious infection (Pro-SEPS). Ongoing study 1 December 2009.
83. NCT01139489 {published data only}
84. Safety and efficacy of procalcitonin guided antibiotic therapy in adult intensive care units (ICUs) (SAPS). Ongoing study November 2009.
85. NCT01379547 {unpublished data only}
86. Procalcitonin to shorten antibiotics duration in ICU patients (ProShort). Ongoing study 21 June 2011.
87. Additional references
88. Arnold 2005
89. Arnold SR, Straus SE. Interventions to improve antibiotic prescribing practices in ambulatory care. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD003539.pub2]
90. Cals 2009
91. Cals JW, Butler CC, Hopstaken RM, Hood K, Dinant GJ. Effect of point of care testing for C reactive protein and training in communication skills on antibiotic use in lower respiratory tract infections: cluster randomised trial. BMJ 2009;338:b1374.
92. Classen 2010
93. Classen DC, Jaser L, Budnitz DS. Adverse drug events among hospitalized Medicare patients: epidemiology and national estimates from a new approach to surveillance. Joint Commission Journal on Quality and Patient Safety/Joint Commission Resources 2010;36(1):12-21.
94. Dixon 1985
95. Dixon RE. Economic costs of respiratory tract infections in the United States. American Journal of Medicine 1985;78(6B):45-51.
96. Doan 2012
97. Doan Q, Enarson P, Kissoon N, Klassen TP, Johnson DW. Rapid viral diagnosis for acute febrile respiratory illness in children in the Emergency Department. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD006452.pub3]
98. Evans 2002
99. Evans AT, Husain S, Durairaj L, Sadowski LS, Charles-Damte M, Wang Y. Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial. Lancet 2002;359(9318):1648-54.
100. Filippini 2006
101. Filippini M, Masiero G, Moschetti K. Socioeconomic determinants of regional differences in outpatient antibiotic consumption: evidence from Switzerland. Health Policy 2006;78(1):77-92.
102. Gonzales 1997
103. Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA 1997;278(11):901-4.
104. Goossens 2005
105. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005;365(9435):579-87.
106. Higgins 2003
107. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
108. Higgins 2011
109. Higgins JPT, Green S (Editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org 2011.
110. Hoare 2006
111. Hoare Z, Lim WS. Pneumonia: update on diagnosis and management. BMJ 2006;332(7549):1077-9.
112. Konstantinides 2008
113. Konstantinides S. Clinical practice. Acute pulmonary embolism. New England Journal of Medicine 2008;359(26):2804-13.
114. Kumar 2006
115. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al.Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Critical Care Medicine 2006;34(6):1589-96.
116. Kumar 2009
117. Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, et al.Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009;136(5):1237-48.
118. Lawrence 2009
119. Lawrence KL, Kollef MH. Antimicrobial stewardship in the intensive care unit: advances and obstacles. American Journal of Respiratory and Critical Care Medicine 2009;179(6):434-8.
120. Liberati 2009a
121. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al.The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of Clinical Epidemiology 2009;62(10):e1-34.
122. Liberati 2009b
123. Liberati A, D'Amico R, Pifferi S, Torri V, Brazzi L, Parmelli E. Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD000022.pub3]
124. Little 1007
125. Little P, Williamson I, Warner G, Gould C, Gantley M, Kinmonth AL. Open randomised trial of prescribing strategies in managing sore throat. BMJ 1997;314(7082):722-7.
126. Macfarlane 1993
127. Macfarlane JT, Colville A, Guion A, Macfarlane RM, Rose DH. Prospective study of aetiology and outcome of adult lower respiratory tract infections in the community. Lancet 1993;341:511-4.
128. Manzano 2010
129. Manzano S, Bailey B, Girodias JB, Galetto-Lacour A, Cousineau J, Delvin E. Impact of procalcitonin on the management of children aged 1 to 36 months presenting with fever without source: a randomized controlled trial. American Journal of Emergency Medicine 2010;28(6):647-53.
130. Muller 2000
131. Muller B, Becker KL, Schachinger H, Rickenbacher PR, Huber PR, Zimmerli W, et al.Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Critical Care Medicine 2000;28(4):977-83.
132. Muller 2001
133. Muller B, Becker KL. Procalcitonin: how a hormone became a marker and mediator of sepsis. Swiss Medical Weekly 2001;131(41-2):595-602.
134. Muller 2010
135. Muller F, Christ-Crain M, Bregenzer T, Krause M, Zimmerli W, Mueller B, et al.Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest 2010;138(1):121-9.
136. RevMan 2011
137. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
138. Roberts 2009
139. Roberts RR, Hota B, Ahmad I, Scott RD 2nd, Foster SD, Abbasi F, et al.Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clinical Infectious Diseases 2009;49(8):1175-84.
140. Schuetz 2010b
141. Schuetz P, Albrich W, Christ-Crain M, Chastre J, Mueller B. Procalcitonin for guidance of antibiotic therapy. Expert review of anti-infective therapy 2010;8(5):575-87.
142. Schuetz 2011
143. Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Archives of Internal Medicine 2011;171(15):1322-31.
144. Spurling 2010
145. Spurling GKP, Del Mar CB, Dooley L, Foxlee R. Delayed antibiotics for respiratory infections. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD004417.pub3]
146. Thompson 2001
147. Thompson SG, Turner RM, Warn DE. Multilevel models for meta-analysis, and their application to absolute risk differences. Statistical Methods in Medical Research 2001;10(6):375-92.
148. Turner 2000
149. Turner RM, Omar RZ, Yang M, Goldstein H, Thompson SG. A multilevel model framework for meta-analysis of clinical trials with binary outcomes. Statistics in Medicine 2000;19(24):3417-32.